Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033367 · ClinicalTrials.gov registry record · Phase 4
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 188
- Enrollment target
NCT04033367 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 188 participants.
The verdict
NCT04033367, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 188 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD). Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation. To continue to assess the safety and tolerability throughout the study.
Interventions
- DRUG Placebo
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04033367
The ClinicalTrials.gov registry entry for NCT04033367 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04033367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04033367 about?
NCT04033367 is a clinical study titled "SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"". Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD). Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime conse...
What is the current status of trial NCT04033367?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2019-08-22. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT04033367?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT04033367?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.